ARCADE (20090160): A randomized controlled trial of darbepoetin alpha in anemic patients with low or intermediate-1 risk myelodysplastic syndrome (MDS)

被引：1
|
作者：
Gasal, E. [1 ]
Pan, C. [2 ]
Tankersley, C. [1 ]
机构：
[1] Amgen Inc, Global Dev, Thousand Oaks, CA 91320 USA
[2] Amgen Inc, Biostat, Thousand Oaks, CA 91320 USA
来源：
LEUKEMIA RESEARCH | 2013年 / 37卷
关键词：
D O I：
10.1016/S0145-2126(13)70367-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-320
引用
收藏
页码：S166 / S167
页数：2
相关论文
共 50 条
  • [1] ARCADE (20090160): A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND TRIAL OF DARBEPOETIN ALFA IN THE TREATMENT OF ANEMIA IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS)
    Platzbecker, U.
    Symeonidis, A.
    Oliva, E.
    Goede, J. S.
    Delforge, M.
    Mayer, J.
    Badre, S.
    Gasal, E.
    Mehta, B.
    Franklin, J.
    [J]. HAEMATOLOGICA, 2016, 101 : 15 - 15
  • [2] A PHASE 3 RANDOMIZED PLACEBO (PBO)-CONTROLLED DOUBLE-BLIND TRIAL OF DARBEPOETIN ALFA IN LOW OR INTERMEDIATE-1 (INT-1) RISK MYELODYSPLASTIC SYNDROMES (MDS)
    Platzbecker, U.
    Symeonidis, A.
    Oliva, E.
    Goede, J.
    Delforge, M.
    Mayer, J.
    Slama, B.
    Badre, S.
    Gasal, E.
    Mehta, B.
    Franklin, J.
    [J]. LEUKEMIA RESEARCH, 2017, 55 : S29 - S30
  • [3] A PHASE 3 RANDOMIZED PLACEBO (PBO)-CONTROLLED DOUBLE-BLIND TRIAL OF DARBEPOETIN ALFA IN LOW OR INTERMEDIATE-1 (INT-1) RISK MYELODYSPLASTIC SYNDROMES (MDS)
    Platzbecker, U.
    Symeonidis, A.
    Oliva, E.
    Goede, J.
    Delforge, M.
    Mayer, J.
    Slama, B.
    Badre, S.
    Gasal, E.
    Mehta, B.
    Franklin, J.
    [J]. HAEMATOLOGICA, 2017, 102 : 484 - 484
  • [4] An Integrated Analysis of Darbepoetin Alfa (DAR) in the Treatment of Anemia in Patients with Low- or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS)
    Platzbecker, Uwe
    Symeonidis, Argiris
    Goede, Jeroen Simon
    Guerci-Bresler, Agnes
    Delforge, Michel
    Oliva, Esther Natalie
    Mayer, Jiri
    Badre, Sejal
    Mehta, Bhakti
    Brandao, Cisio De Oliveira
    [J]. BLOOD, 2017, 130
  • [5] A Phase 3 Randomized Placebo (PBO)-Controlled Double-Blind Trial of Darbepoetin Alfa in the Treatment of Anemia in Patients with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndromes (MDS)
    Platzbecker, Uwe
    Symeonidis, Argiris
    Oliva, Esther N.
    Goede, Jeroen S.
    Delforge, Michel
    Mayer, Jiri
    Slama, Borhane
    Badre, Sejal
    Gasal, Eduard
    Mehta, Bhakti
    Franklin, Janet
    [J]. BLOOD, 2016, 128 (22)
  • [6] Baseline predictors of response to treatment with darbepoetin-alpha (DA) in anemic patients with low-risk myelodysplastic syndrome (MDS)
    Gabrilove, J.
    Paquette, R.
    Lyons, R.
    Mushtaq, C.
    Sekeres, M.
    Tomita, D.
    Lillie, T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] A Randomized Study to Determine the Optimal Dose of Darbepoetin Alfa in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes
    Harada, Hironori
    Shibayama, Hirohiko
    Jang, Jun Ho
    Shimazaki, Ryutaro
    Mitani, Kinuko
    Sawada, Kenichi
    Kim, Hyeoung-Joon
    [J]. BLOOD, 2014, 124 (21)
  • [8] A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes
    Jun Ho Jang
    Hironori Harada
    Hirohiko Shibayama
    Ryutaro Shimazaki
    Hyeoung-Joon Kim
    Kenichi Sawada
    Kinuko Mitani
    [J]. International Journal of Hematology, 2015, 102 : 401 - 412
  • [9] A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes
    Jang, Jun Ho
    Harada, Hironori
    Shibayama, Hirohiko
    Shimazaki, Ryutaro
    Kim, Hyeoung-Joon
    Sawada, Kenichi
    Mitani, Kinuko
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 102 (04) : 401 - 412
  • [10] Outcome Of Patients (pts) With Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Xiao, Lianchun
    Najla, Al Ali
    Mishra, Asmita
    Padron, Eric
    Lancet, Jeffrey E.
    Bryan, Jeffery
    Prescott, Hillary
    Steensma, David P.
    Sekeres, Mikkael A.
    Roboz, Gail J.
    List, Alan
    Kantarjian, Hagop M.
    Komrokji, Rami S.
    [J]. BLOOD, 2013, 122 (21)
12345